Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

By A. Malmström, B. H. Grønberg, C. Marosi, R. Stupp, D. Frappaz, H. Schultz, U. Abacioglu, B. Tavelin, B. Lhermitte, M. Hegi and 2 more. The Lancet Oncology, 2012

1,139 citations recorded by the source corpus.

Subfields: Genetics, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/6caadca575ee3b79cf8a002ab9d41c69281bf7cb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Jill S. Barnholtz-Sloan
2. Q. Ostrom
3. Guido Reifenberger

Citations in the corpus

• Epidemiologic and Molecular Prognostic Review of Glioblastoma (2014, background): “EGFR over-expression was associated with worse prognosis in younger patients and better prognosis in older patients (41, 72, 127).”
• Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “Similar results have been found in elderly patients, showing improved outcome with chemotherapy treatment in MGMT promoter-methylated tumors, while worse survival was associated with unmethylated tumors [105, 174], suggesting that MGMT promoter methylation is not a prognostic, but instead a predicti”
• High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, methodology): “Prognosis of mixed anaplastic oligoastrocytoma and anaplastic astrocytoma is intermediate between GBM and pure anaplastic oligodendroglioma.”